Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
SAGE Therapeutics (SAGE) Gets a Buy from Scotiabank
Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.
Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Sage stock price target cut to $12 by H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...
TipRanks on MSN6d
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
SAGE Therapeutics, Inc. (US) (SAGE) has disclosed a new risk, in the Litigation & Legal Liabilities category. SAGE Therapeutics, Inc. is currently ...
kalkinemedia4d
Is Sage Therapeutics (NASDAQ:SAGE) Facing a Turning Point in the Market?
Highlights,Institutional investors have adjusted their holdings in Sage Therapeutics.,The company reported a negative net ...